Purple Biotech (PPBT) News Today → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free PPBT Stock Alerts $0.52 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinePurple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meetingglobenewswire.com - April 25 at 7:00 AMPurple Biotech (NASDAQ:PPBT) Trading Up 8.1%americanbankingnews.com - April 24 at 2:18 AMPurple Biotech Ltd (PPBT)investing.com - April 17 at 11:15 PMPurple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024finance.yahoo.com - March 28 at 11:13 AMPurple Biotech Ltd.: Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technologyfinanznachrichten.de - March 14 at 12:40 PMPurple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technologyglobenewswire.com - March 14 at 7:30 AMPPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023investorplace.com - March 5 at 11:52 PMPurple Biotech Ltd.: Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Resultsfinanznachrichten.de - March 5 at 1:22 PMPurple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Resultsglobenewswire.com - March 5 at 7:55 AMPurple Biotech ADR (PPBT) Earnings Dates & Reportsinvesting.com - March 3 at 6:09 PMBuy Rating Justified by Promising Phase 1 Results of Purple Biotech’s NT219 in SCCHN Treatmentmarkets.businessinsider.com - February 27 at 10:57 PMPurple Biotech Ltd ADRmorningstar.com - February 27 at 5:56 PMPurple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024globenewswire.com - February 27 at 7:00 AMPurple Biotech Ltd. ADRwsj.com - February 22 at 2:20 PMPurple Biotech Ltd ADR PPBTmorningstar.com - February 15 at 12:30 AMPurple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trialfinance.yahoo.com - February 13 at 8:34 AMAnalysts Offer Insights on Healthcare Companies: Purple Biotech (PPBT) and Sanofi (OtherSNYNF)markets.businessinsider.com - February 1 at 5:47 PMPurple Biotech stock climbs 9% on Phase 2 study updatemsn.com - February 1 at 12:47 PMPurple Biotech Reaches Recommended Phase 2 Dose for NT219finance.yahoo.com - February 1 at 7:47 AMPurple Biotech Appoints Dr. Yael Margolin to its Board of Directorsfinance.yahoo.com - December 20 at 9:18 AMPurple Biotech Ltd.: Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trialfinanznachrichten.de - December 14 at 10:30 AMPurple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trialfinance.yahoo.com - December 14 at 10:30 AMPromising Clinical Trial Results and Accelerated Enrollment Boost Purple Biotech’s Buy Ratingmarkets.businessinsider.com - November 22 at 7:58 AMPurple Biotech Reports Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 21 at 10:25 AMPurple Biotech Fortifies NT219 Patent Protectionfinance.yahoo.com - November 2 at 10:41 AMPurple Biotech Announces Closing of $5 Million Registered Direct Offeringfinance.yahoo.com - October 19 at 5:53 PMPurple Biotech Shares Drop 16% After Direct Offering Pricesmarketwatch.com - October 17 at 12:45 PMPurple Biotech announces $5M direct offering to fund oncology therapeutic candidatesmsn.com - October 17 at 12:45 PMPurple Biotech Announces $5 Million Registered Direct Offeringfinance.yahoo.com - October 17 at 12:45 PMPurple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Actionfinance.yahoo.com - October 6 at 9:01 AMPurple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancerfinance.yahoo.com - October 3 at 8:55 AMPurple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023finance.yahoo.com - September 21 at 9:59 AMH.C. Wainwright Remains a Buy on Purple Biotech (PPBT)markets.businessinsider.com - August 30 at 4:22 PMPurple Biotech Ltd.: Purple Biotech Reports Second Quarter 2023 Financial Resultsfinanznachrichten.de - August 22 at 4:30 PMIsrael's Purple reports encouraging early data for pancreatic cancer drugmsn.com - July 11 at 7:15 PMPurple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patientsfinance.yahoo.com - July 11 at 9:10 AMPurple Biotech Ltd.: Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Updatefinanznachrichten.de - May 17 at 10:06 AMPurple Biotech: Q1 Earnings Insightsmsn.com - May 16 at 8:05 PMPurple Biotech Reports First Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - May 16 at 8:05 PMPurple Biotech Debuts Scientific Advisory Boardfinance.yahoo.com - April 25 at 11:12 AMPurple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitorsfinance.yahoo.com - April 19 at 12:27 PMPurple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conferencefinance.yahoo.com - April 18 at 8:01 AMPurple Biotech Taps Israel as Acting CEO With Efron on Medical Leavemarketwatch.com - March 24 at 3:35 PMPurple Biotech Reports Temporary Medical Leave of CEO Gil Efronfinance.yahoo.com - March 24 at 10:35 AMPurple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Studyfinance.yahoo.com - March 16 at 10:30 AMPurple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trialfinance.yahoo.com - February 14 at 8:45 AMPurple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancerfinance.yahoo.com - February 2 at 10:00 AMPurple Biotech stock rises on team up with Mor for research on cancer drugsmsn.com - January 3 at 1:23 PMPurple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatmentsfinance.yahoo.com - January 3 at 8:23 AMPurple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasisfinance.yahoo.com - November 15 at 9:11 AM Get Purple Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter. Email Address It’s now possible to know the win rate of every trade… BEFORE you take it! (Ad)Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << PPBT Media Mentions By Week PPBT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PPBT News Sentiment▼0.000.41▲Average Medical News Sentiment PPBT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PPBT Articles This Week▼20▲PPBT Articles Average Week Get Purple Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Imunon News Today RedHill Biopharma News Today AgeX Therapeutics News Today MIRA Pharmaceuticals News Today Tonix Pharmaceuticals News Today Avalo Therapeutics News Today Monopar Therapeutics News Today NanoViricides News Today Eterna Therapeutics News Today Galera Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PPBT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Purple Biotech Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
